Cargando…

A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors

The rubric of immune-related (ir) diabetes mellitus (DM) (irDM) encompasses various hyperglycemic disorders related to immune checkpoint inhibitors (ICPis). Beyond sharing similarities with conventional DM, irDM is a distinct, yet important, entity. The present narrative review provides a comprehens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deligiorgi, Maria V., Trafalis, Dimitrios T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146255/ https://www.ncbi.nlm.nih.gov/pubmed/37108792 http://dx.doi.org/10.3390/ijms24087630

Ejemplares similares

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
por: Deligiorgi, Maria V., et al.
Publicado: (2021)

The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research
por: Deligiorgi, Maria V., et al.
Publicado: (2021)

The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum
por: Deligiorgi, Maria V., et al.
Publicado: (2022)

How Far Are We from Prescribing Fasting as Anticancer Medicine?
por: Deligiorgi, Maria V., et al.
Publicado: (2020)

Charting the Unknown Association of COVID-19 with Thyroid Cancer, Focusing on Differentiated Thyroid Cancer: A Call for Caution
por: Deligiorgi, Maria V., et al.
Publicado: (2021)

Immune checkpoint inhibitor–induced diabetes mellitus with pembrolizumab
por: Zand Irani, Anis, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
por: Zand Irani, Anis, et al.
Publicado: (2023)

Assessment of Methodological Pipelines for the Determination of Isothiocyanates Derived from Natural Sources
por: Kyriakou, Sotiris, et al.
Publicado: (2022)

Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
por: Fujita, Yasunori, et al.
Publicado: (2023)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
por: Imagawa, Akihisa
Publicado: (2020)

An Evaluation of the Anti-Carcinogenic Response of Major Isothiocyanates in Non-Metastatic and Metastatic Melanoma Cells
por: Mitsiogianni, Melina, et al.
Publicado: (2021)

Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation
por: Trafalis, Dimitrios T., et al.
Publicado: (2021)

SUN-170 Development of Type 1 Diabetes Mellitus on Immune Checkpoint Inhibitor
por: Tsuei, Jessica, et al.
Publicado: (2019)

Spindle checkpoint silencing: ensuring rapid and concerted anaphase onset
por: Hardwick, Kevin G, et al.
Publicado: (2010)

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
por: Fang, Wei, et al.
Publicado: (2023)

Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice
por: Rodríguez de Vera-Gómez, Pablo, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
por: Mourad, Diane, et al.
Publicado: (2021)

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
por: de Filette, Jeroen M K, et al.
Publicado: (2019)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay
por: Nikoleousakos, Nikolaos, et al.
Publicado: (2021)

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden
por: Sagredou, Sofia, et al.
Publicado: (2021)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
por: Inaba, Hidefumi, et al.
Publicado: (2022)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus
por: Muniz, Thiago P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy
por: Alrifai, Taha, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Associated Type 1 Diabetes
por: Duenas, Jose Andres, et al.
Publicado: (2021)

SAT-667 Partial Beta-Cell Destruction: An Atypical Case of Immune Checkpoint Inhibitor Diabetes Mellitus
por: Quandt, Zoe, et al.
Publicado: (2020)

Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
por: Okubo, Marie, et al.
Publicado: (2022)

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
por: Hilder, Robin, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors for bone sarcoma therapy
por: Thanindratarn, Pichaya, et al.
Publicado: (2019)

Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gkss4229q6faqjlccn3aaq7k2o